Immunotherapy developer Arcus Biosciences, backed by Stanford University, has raised series C funding from a GV-led consortium that included Celgene and Taiho.
Arcus Biosciences, a US-based cancer-focused biotechnology producer backed by Stanford University, raised $107m in series D capital yesterday from investors led by GV, the early-stage investment arm of internet and technology conglomerate Alphabet.
The round, which took the company’s overall funding to $227m, also featured pharmaceutical firms Celgene and Taiho, the latter participating through its Taiho Ventures unit.
Wellington Management, EcoR1 Capital, BVF Partners, Decheng Capital, Hillhouse, Aisling Capital, Column Group, Foresite Capital, Invus Opportunities, Droia Oncology Ventures and entities affiliated…
